Wire · operational-macro
Medtech M&A rebounds in second quarter as strategic buyers drive activity
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
Medtech M&A activity in Q2 2026 surged with 113 transactions, driven mainly by strategic buyers and private equity add-ons. Deal valuations increased despite a decline in public-market medtech indices, while supply chain and tariff concerns shifted buyer focus to U.S.-based manufacturers.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
Medtech dealmakers have pivoted sharply toward U.S. manufacturers to avoid tariff risks and supply disruptions. You should revisit your supply chain strategy and M&A targets this quarter to stay ahead of buyer preferences.
◆ Coverage
1 source · 14 Sep 2026
◆ Related on Wire
◆ Topics